Hylazine

Quick links to important sections

Hylazine

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hylazine

Quick Facts

Property Description
Active Ingredient Hydralazine Hydrochloride
Pharmacological Class Antihypertensive Agent, Direct Vasodilator
Origin Synthetic Compound (Phthalazine Derivative)
Dosage Forms Tablet (oral), Injectable Solution (parenteral)
General Purpose To lower systemic high blood pressure

Hylazine: Classification and Identity of the Active Ingredient

Hylazine is a prescription-only medicine whose active ingredient, Hydralazine Hydrochloride, is a synthetic compound derived from the phthalazine chemical structure. Pharmacologically, Hylazine is classified within the broad group of antihypertensive agents, with the specific distinction of being a direct-acting vasodilator. This mechanism sets the drug apart from classes like ACE inhibitors or beta-blockers, establishing its specific role in managing elevated blood pressure.

What Types of Pharmaceutical Preparations Does Hylazine Come In?

As a single-ingredient product, Hylazine is prepared in several dosage forms suitable for systemic delivery. It is primarily available in tablets for consistent oral administration. A key differentiating factor is its availability as a sterile injectable solution for parenteral administration, which is clinically recognized for use when rapid intervention is required. The medication’s composition centers on the Hydralazine entity, supported by either standard pharmaceutical excipients in the solid forms or an aqueous solution base/vehicle for the injection.

General Purpose: What Does Hylazine Help to Achieve?

The fundamental action of Hylazine is to cause the arteries to relax and widen, resulting in a crucial reduction of peripheral vascular resistance (PVR). This physiological effect defines the general purpose of this specialized antihypertensive agent: to reduce the mechanical resistance in the blood vessels, thereby relieving the excessive strain placed on the cardiovascular system by high and persistent systemic high blood pressure elevations.

What side effects are possible with Hylazine?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics of Hydralazine Hydrochloride (Hylazine), as defined by governmental regulatory authorities like the FDA and EMA. The information is structured according to established regulatory safety classifications.


Frequency and System-Organ Classifications

The possible adverse reactions are formally classified by frequency and the physiological system affected. Very Common effects, often observed at the initiation of therapy or during dose escalation, include headache, palpitations, and tachycardia (rapid heart rate). Common effects documented in regulatory labeling include flushing, dizziness, hypotension (low blood pressure), and gastrointestinal disturbances such as nausea and diarrhoea.

System-Organ Class Examples of Documented Effects
Cardiac Disorders Tachycardia, palpitations, angina pectoris
Nervous System Disorders Headache, dizziness, peripheral neuritis
Gastrointestinal Disorders Nausea, vomiting, diarrhoea
Immune System/Blood SLE-like syndrome, anaemia, leucopenia

Serious Adverse Reactions and Restrictions

Regulatory documentation highlights serious adverse reactions, notably the Systemic Lupus Erythematosus (SLE)-like syndrome, which is primarily associated with prolonged treatment and higher doses. Other serious effects include severe blood dyscrasias (e.g., agranulocytosis) and the potential to provoke or aggravate angina pectoris in susceptible individuals. Hylazine is formally contraindicated in patients with pre-existing idiopathic SLE, coronary artery disease (CAD), or certain valvular heart diseases. Caution is also advised for use in older adults and those with advanced renal or hepatic dysfunction.

Overdose and Emergency Response

Overdose and when to seek help

The official government regulatory documents state that an overdose of Hylazine (Hydralazine Hydrochloride) is characterized by an exaggerated physiological effect on the cardiovascular system.

Documented Clinical Manifestations

Overdose manifestations are formally documented as a cluster of signs that reflect severe vasodilation.

Clinical Sign Potential Severe Outcome
Profound hypotension (severely low blood pressure) Myocardial ischemia and myocardial infarction (heart attack)
Tachycardia (abnormally fast heart rate) Cardiac arrhythmia (irregular heart rhythm)
Headache and generalized skin flushing Profound shock

Immediate Medical Intervention

The potential for life-threatening complications, including profound shock, cardiac arrhythmia, and myocardial infarction, mandates that immediate medical attention must be sought when an overdose is suspected. Due to these serious risks, the regulator requires contact with emergency services.

Officially Described Management

No specific antidote is known for Hylazine overdose; therefore, management is focused on symptomatic and supportive treatment. Support of the cardiovascular system is of primary importance. Regulatory instructions describe treating shock with plasma expanders (intravenous fluids). Furthermore, if vasopressors are required to raise blood pressure, careful administration is necessary to avoid precipitating or aggravating cardiac arrhythmia. Tachycardia or signs of ischemia may be managed with beta blockers.

Therapeutic Uses of Hylazine

What Hylazine Treats: Main Uses and Benefits

Hylazine is a specialized agent generally reserved for complex cardiovascular situations where enhanced pressure control may be crucial. It is commonly used to help manage high blood pressure and may be applied in the treatment of heart failure. It directly assists with relieving symptoms related to systemic imbalance, thereby relieving symptoms linked to organ-specific functional stress.

Managing Acute and Critical Symptomatic Episodes

This agent is relevant for managing conditions characterized by periods of heightened symptoms, including hypertensive urgency and emergency, refractory hypertension, and severe hypertension during pregnancy (such as preeclampsia). Hylazine may assist with providing supportive pressure control during episodes of sudden symptom escalation. The core benefit is to support a sense of stability when symptoms are more noticeable in these challenging symptomatic phases.

Supportive Therapy in Advanced Symptomatic Domains

It also plays a role in managing symptoms linked to organ-specific functional stress for patients with Heart Failure with Reduced Ejection Fraction (HFrEF). When used in combination, it supports improved day-to-day comfort and contributes to easing the overall symptom load for conditions marked by temporary physiological imbalance.


Quick Fact: Relief for Vascular Strain

Feature Description
Primary Focus Managing symptoms related to heightened physiological activity and excessive arterial pressure.
Clinical Context Applied in clinical settings that involve acute or unstable symptom patterns.
Benefit Contributes to improved comfort by easing the overall symptom burden of severe high blood pressure.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Hylazine use is defined by strict regulatory criteria, primarily applying to specific adult populations. The medicine is contraindicated and must not be used by individuals with certain cardiovascular conditions, including established Coronary Artery Disease (CAD), Mitral Valvular Rheumatic Heart Disease, or severe tachycardia. Absolute prohibitions also apply to patients with certain forms of Systemic Lupus Erythematosus (SLE) and myocardial insufficiency due to mechanical obstruction.


Age and Physiological Restrictions

The official regulatory status for pediatric patients is that safety and effectiveness have not been established in controlled clinical trials, and use is not generally recommended. For older adults, caution is advised due to potential increased sensitivity and possible diminished renal function.

In the context of pregnancy, Hylazine is avoided during the first and second trimesters. Its use is limited to the third trimester for specific high-risk conditions when the benefit outweighs the risk. During lactation, the drug is excreted into human milk, requiring use with caution. Furthermore, patients with advanced renal damage or hepatic dysfunction require cautious use due to labeled limitations regarding the body’s processing of the medicine.

What should I know about interactions with other medicines?

Hylazine Interactions with Other Medicines and Products: Official Domains

Regulatory information documents specific interaction patterns for Hylazine (Hydralazine Hydrochloride), primarily concerning additive blood pressure effects and drug exposure modification.


Documented Interaction Patterns

Interaction Type Interacting Categories/Substances
Additive Hypotension Other Antihypertensive Agents, Anaesthetics, Tricyclic Antidepressants, Major Tranquilisers, and Alcohol.
Antagonism of Effect Certain Non-steroidal Anti-inflammatory Agents (NSAIDs), such as Indometacin.
Increased Co-Drug Exposure Beta-blockers (e.g., propranolol) that undergo significant first-pass metabolism.

Exposure Modification and Precautions

Food taken with Hylazine results in higher plasma levels (increased systemic exposure). Due to this exposure factor, patients who are slow acetylators are also noted to have higher plasma concentrations of Hylazine. While no combinations are formally classified as a contraindication based on interaction risk, combining injectable Hylazine with potent parenteral hypotensives like diazoxide requires continuous observation for several hours due to the risk of excessive pressure reduction. Additionally, combining Hylazine with certain beta-blockers may require a downward dose adjustment of the beta-blocker because Hylazine increases its bioavailability.

Mechanism of Action

Intracellular Modulation of Arterial Smooth Muscle

Hydralazine's primary mechanism is exerted within vascular smooth muscle cells (VSMC) in resistance arterioles. The molecule acts as an inhibitor to reduce the release of intracellular calcium (Ca^2+) from the sarcoplasmic reticulum, functionally decreasing the Ca^2+ available for the contractile apparatus. This molecular effect leads directly to the relaxation of the smooth muscle.

Selective Reduction of Peripheral Vascular Resistance (PVR)

This cellular relaxation cascade results in immediate and profound vasodilation highly selective for the arterial circulation. This physiological consequence translates into a significant reduction of Peripheral Vascular Resistance (PVR), which reduces the overall systemic pressure.

Engagement of Compensatory Physiological Reflexes

The rapid drop in PVR triggers the Baroreceptor Reflex, leading to the reflex activation of the Sympathetic Nervous System (SNS) and the Renin-Angiotensin-Aldosterone System (RAAS). This compensatory action serves as a physiological limitation, causing an increase in heart rate and promoting volume retention.

Modulation of Novel Enzyme and Regulatory Pathways

Beyond the core Ca^2+ effect, the drug modulates enzymes like 2-Aminoethanethiol Dioxygenase (ADO) and Prolyl Hydroxylase Domain (PHD) enzymes. This involves interference with gene regulatory factors, such as HIF-1alpha, contributing a secondary layer to the long-term cellular adaptation and vascular regulatory profile.

Dosage and Administration Information

Official Administration Guidelines

Hydralazine is provided for use as oral tablets (10 mg, 25 mg, 50 mg, 100 mg) and as a sterile injection (20 mg/mL) for parenteral administration. The approved routes are Oral, Intramuscular (IM), or as a rapid Intravenous (IV) bolus injection.

Dosing and Frequency

  • Adult Oral Titration: Therapy typically begins with 10 mg four times a day (q.i.d.) for the first 2 to 4 days, then increases to 25 mg q.i.d. for the remainder of the first week. The dose is then gradually increased to a maintenance level, usually up to 50 mg q.i.d. The total daily dose should not exceed 200 mg for most patients.
  • Parenteral Use: When an urgent need arises and the drug cannot be given orally, the usual dose is 20 to 40 mg IM or rapid IV injection, which may be repeated as necessary.
  • Pediatric Dosing: Dosage is based on body weight, starting at approximately 0.75 mg/kg per day divided into four doses, not to exceed 7.5 mg/kg daily or 200 mg per day.

Administration Conditions

  • Timing in Relation to Meals: Oral tablets should be taken consistently with respect to meals to ensure uniform absorption (either always with food or always without food). Taking the medication with food is a recognized approach.
  • Special Adjustments: A lower dose may be required for patients with marked renal damage or for individuals known to be slow acetylators (those who metabolize the drug slowly).
  • Parenteral Preparation: The injectable solution must be used immediately after opening the vial. It should not be added to intravenous infusion solutions, and any solution that has changed color after contact with metal should be discarded.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hylazine

Overview of Clinical Research for Chronic Heart Failure

Hylazine was evaluated in research exploring its use as an added agent for patients with chronic heart failure where the heart does not pump blood efficiently, a condition known as Heart Failure with Reduced Ejection Fraction (HFrEF). The core evidence in this area comes from large-scale Randomized Controlled Trials (RCTs). These studies explored Hylazine primarily in combination with a nitrate drug, comparing this regimen against a non-active placebo control, in populations already receiving other standard medications.

Research examined outcomes related to systemic or functional imbalance, including all-cause mortality and the frequency of hospitalization due to heart failure. Studies reported measurements where findings described patterns observed in the combination therapy group compared to the placebo group regarding mortality and hospitalization rates. The existing evidence base has limited information regarding the long-term impact of Hylazine monotherapy (used alone) on major clinical outcomes.

Evidence for Acute Blood Pressure Management

Hylazine was evaluated in research settings involving conditions associated with acute or disruptive episodes where blood pressure levels require prompt evaluation. Studies explored the use of Hylazine in conditions characterized by fluctuating or unstable symptoms, such as when hypertension is refractory (resistant) to standard treatments. This research often relied on retrospective reviews and observational data where healthcare providers monitored patients to evaluate outcomes related to systemic or functional imbalance.

Research in Severe Hypertension During Pregnancy

This sub-section specifically outlines the comparative trials and systematic reviews that have evaluated Hylazine's use in conditions associated with acute or disruptive episodes of high blood pressure in pregnant patients. Hylazine was studied for the specific context of severe hypertension during pregnancy, including preeclampsia and eclampsia. Study designs included RCTs that compared Hylazine against other acute-acting medications. Studies monitored the time to achieve target blood pressure and outcomes linked to physiological strain or stress on the mother and fetus.

Consistency and Gaps in the Evidence Base

While some research describes consistent patterns observed in studies regarding the use of Hylazine in combination for heart failure, the evidence base is not uniform across all uses. Certainty remains low for long-term patient-centered outcomes in essential hypertension; key modern RCTs addressing this are absent. Key limitations exist where comparative evidence is lacking against current standard-of-care treatments for several conditions. Furthermore, study results, particularly in acute settings, were mixed regarding the speed and consistency of changes measured during the study period.

Key Studies & References

  1. Drugs for treatment of very high blood pressure during pregnancy (Cochrane Review)
  2. Hydralazine: MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Hylazine (FAQ)

Q: Is Hylazine used for any conditions besides the primary approved one?

A: According to regulatory documents, Hylazine is primarily indicated for the treatment of essential hypertension (high blood pressure). Official information also notes its use in the management of severe hypertension and in combination with other agents for specific patient populations with chronic heart failure.

Q: How does Hylazine compare generally to other medicines for the same condition?

A: Official documents classify Hylazine as a direct-acting peripheral vasodilator. This means its mechanism involves directly causing the smooth muscle in the arteries to relax, which is a different class of action than other common medications used for high blood pressure, such as ACE inhibitors or beta-blockers.

Q: Is Hylazine considered a long-term treatment option?

A: Hylazine is indicated for chronic conditions like essential hypertension, suggesting it is intended for long-term use, though a short-term injectable form is also available. However, official information notes that the risk of certain serious side effects, such as a Systemic Lupus Erythematosus (SLE)-like syndrome, is associated with prolonged treatment and higher total doses.

Q: Do the side effects of Hylazine go away over time?

A: Official safety data indicates that many of the reported adverse reactions, such as headache and nausea, may be reversible when the dosage is reduced. While side effects are often more prominent at the beginning of therapy, regulatory documents do not provide a guarantee that all side effects will subside over time.

Q: Can Hylazine be taken with common over-the-counter pain relievers?

A: Regulatory documents list a potential interaction where the blood pressure-lowering effect of Hylazine may be reduced or antagonized by certain Non-steroidal Anti-inflammatory Agents (NSAIDs), which are common over-the-counter pain relievers. Regulatory information emphasizes the importance of disclosing all current medications to a healthcare provider.

Q: What food or supplements might interact with Hylazine?

A: Official product information states that taking Hylazine with food is known to increase the concentration of the drug in the body. Official documents emphasize the importance of disclosing all concurrent medications, including vitamins and herbs, to a healthcare provider, as potential interactions exist, including with Vitamin B6 (Pyridoxine).

Q: If I miss taking Hylazine, what generally happens?

A: General patient advice, based on regulatory guidance, is to take the missed dose as soon as you remember, unless it is almost time for your next scheduled dose. Patient information generally cautions against taking double or extra doses to make up for a missed dose.

Q: What is the typical timeframe for seeing the full effect of Hylazine?

A: For oral administration, peak plasma levels (the highest concentration in the blood) are generally reached within 1 to 2 hours. For chronic treatment, the dose is gradually increased over several days or weeks, meaning the full therapeutic effect is achieved gradually during this titration period.

Q: What is the usual duration of effect for a dose of Hylazine?

A: The length of time Hylazine remains in the system can vary widely among individuals, but regulatory information states that the plasma levels of the drug decline with a half-life typically ranging from 3 to 7 hours.

Q: Is Hylazine an addictive substance or habit-forming?

A: No, Hylazine is not classified as a controlled substance by the DEA (Drug Enforcement Administration) in the United States. Regulatory documents do not indicate that the drug is known to be addictive or habit-forming.

Q: What do researchers say about the long-term effects of Hylazine?

A: The most significant long-term concern noted in the drug label is the development of a Systemic Lupus Erythematosus (SLE)-like syndrome. This rare effect is specifically associated with prolonged treatment and higher total daily doses.

Q: Do patients need special monitoring while using Hylazine?

A: Official regulatory guidance suggests that patients should be checked regularly while taking Hylazine. For instance, blood tests may be needed to monitor for certain rare, unwanted effects, such as blood dyscrasias (blood cell abnormalities) or symptoms mimicking SLE.

Q: Is there a generic version of Hylazine available?

A: Yes. The active ingredient in Hylazine, known as Hydralazine Hydrochloride, is widely available as a generic drug from various manufacturers. The original brand name product is known as Apresoline.

Q: Can Hylazine affect my ability to drive or operate machinery?

A: Because Hylazine can cause side effects like dizziness or impaired reaction time, official patient information advises caution. Official patient information advises caution regarding driving or operating machinery due to possible effects like dizziness or impaired reaction time.

Q: What happens if I stop taking Hylazine suddenly?

A: Official patient information strongly cautions against stopping the medication without first consulting a healthcare professional. Suddenly discontinuing the drug may cause the underlying illness for which it was prescribed to potentially become worse.

Q: Why do people sometimes say Hylazine is 'stronger' than similar drugs?

A: Official information describes the drug's action as causing a direct and profound relaxation of vascular smooth muscle, leading to significant vasodilation. This direct, potent physiological effect is what distinguishes it from other antihypertensive agents and may be the reason for this perception.

Q: Can Hylazine be split or crushed?

A: Official administration instructions generally advise patients to swallow the tablets whole with a glass of water. Regulatory documents typically do not provide explicit instructions or permission to split, crush, or otherwise modify the oral tablets.

Q: What happens if Hylazine is taken by someone who shouldn't use it?

A: Taking Hylazine when a formal contraindication is present (such as pre-existing coronary artery disease) can pose serious risks. Official warnings note that this misuse may lead to an increased risk of issues like myocardial ischemia or the provocation of anginal attacks.

Q: Can Hylazine change my mood?

A: Official regulatory labels list psychotic reactions characterized by depression, disorientation, or anxiety among the less frequent neurologic adverse reactions reported.

Q: What are the common misunderstandings about how Hylazine should be used?

A: Regulatory patient information emphasizes two key points regarding use: the drug must be taken regularly and continuously as prescribed, and the oral tablets should be taken consistently with respect to meals (e.g., always with food or always without it) to ensure uniform absorption.

Q: Does the time of day I take Hylazine matter?

A: Hylazine is often prescribed in divided doses (e.g., four times a day). The divided dosing schedule found in regulatory documents is designed to maintain a consistent therapeutic concentration of the medicine.

Q: Can taking Hylazine make me feel tired or sleepy?

A: While tiredness is not listed as a common side effect, official safety data notes other central nervous system effects such as dizziness and general weakness. These less frequent effects may indirectly impair concentration or make you feel less energetic.

Q: Does Hylazine affect weight or metabolism?

A: Official regulatory data lists anorexia (loss of appetite) and weight loss among the adverse reactions observed in patient groups, though these effects are noted to be less frequent.

How should Hylazine be stored and disposed of?

Hylazine (Hydralazine Hydrochloride) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C. The product must be protected from freezing. Store the medicine in its original container and keep the bottle tightly closed to protect it from moisture and light (particularly the injectable solution). Keep Hylazine out of the sight and reach of children.

For disposal, unused or expired Hylazine must be handled according to local regulations. The medicine should not be flushed down the toilet unless directed to do so by an authorized drug take-back program. If discarding in household trash, official guidance suggests mixing the medicine with an undesirable substance, such as coffee grounds, and placing the mixture in a sealed bag.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hylazine found in:

A-Z Index: